PTGX on Nasdaq

Protagonist Therapeutics, Inc

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Septerna, Inc., Aquestive Therapeutics, Inc. or CUMBERLAND PHARMACEUTICALS INC, or pick any stock.

  • TickerPTGX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNewark, California1
  • Incorporated inDE2
  • Business address7707 Gateway Blvd., Suite 140, Newark, Ca 94560-11602
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-343.6%Operating margin4
-282.8%Net margin4
-89.4%Revenue growth, 20254
-21.2%Return on equity4
$56.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development99¢$159.3M
  • Income tax1¢$838.0K

Out of $46.0M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending3¢$1.6M
  • Kept or used elsewhere97¢$56.1M

Out of $57.7M of cash from operations.4

Financial statements

Revenue56784$46.0M in 2025+19820% since 2019
0$200.0M$400.0M$600.0M2019: $231.0K$231.0K20192020: $28.6M$28.6M2020+12293%2021: $27.4M$27.4M2021−4%2022: $26.6M$26.6M2022−3%2023: $60.0M$60.0M2023+126%2024: $434.4M$434.4M2024+624%2025: $46.0M$46.0M2025−89%
Operating income56784-$158.1M in 2025+96% since 2019
-$200.0M0$200.0M$400.0M2019: -$80.5M-$80.5M20192020: -$64.5M-$64.5M2020−20%2021: -$125.8M-$125.8M2021+95%2022: -$131.4M-$131.4M2022+4%2023: -$93.7M-$93.7M2023−29%2024: $252.8M$252.8M20242025: -$158.1M-$158.1M2025
Net income56784-$130.1M in 2025+69% since 2019
-$200.0M0$200.0M$400.0M2019: -$77.2M-$77.2M20192020: -$66.2M-$66.2M2020−14%2021: -$125.6M-$125.6M2021+90%2022: -$127.4M-$127.4M2022+1%2023: -$79.0M-$79.0M2023−38%2024: $275.2M$275.2M20242025: -$130.1M-$130.1M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
License and collaboration revenue$46.0M$434.4M$60.0M
Research and development$159.3M$138.1M$120.2M
General and administrative$44.9M$43.5M$33.5M
Total operating expenses$204.1M$181.6M$153.7M
(Loss) income from operations-$158.1M$252.8M-$93.7M
Interest income$28.8M$26.3M$14.9M
Other income (expense), net$27.0K$250.0K-$201.0K
(Loss) income before income tax expense-$129.3M$279.4M-$79.0M
Provision for income taxes$838.0K$4.2M
Net (loss) income-$130.1M$275.2M-$79.0M
Net (loss) income per share, basic-$2.05$4.47-$1.39
Net (loss) income per share, diluted-$2.05$4.23-$1.39
Weighted-average shares used to compute net (loss) income per share, basic63.6M shares61.6M shares56.8M shares
Weighted-average shares used to compute net (loss) income per share, diluted63.6M shares65.1M shares56.8M shares

Compare Protagonist Therapeutics, Inc with another company

Leadership

Who has led Protagonist Therapeutics, Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dinesh Ph D. Patel V.2016–now

President

  1. Dinesh Ph D. Patel V.2016–now

Chief financial officer

  1. Thomas P. O'Neil2016–2018
  2. Donald A. Kalkofen2019–2022
20202025
Board members and other officers (18)

Former names

  • Protagonist Therapeutics IncJun 11, 2013 to Jun 11, 20132
  • Protagonist IncSep 28, 2006 to Sep 28, 20062

Timeline

  1. Aug 10, 2016New chief executive Dinesh Ph D. Patel V. becomes CEO12

Filings

352 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 139 insider forms, 56 large holders, 90 other. The latest 20:

  1. Oct 2, 20264 OWNERSHIP DOCUMENT EDGAR
  2. Sep 30, 2026144 EDGAR
  3. Sep 10, 20264 OWNERSHIP DOCUMENT EDGAR
  4. Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
  5. Aug 13, 2026SCHEDULE 13G/A EDGAR
  6. Aug 12, 20264 OWNERSHIP DOCUMENT EDGAR
  7. Aug 10, 2026144 EDGAR
  8. Aug 7, 2026SCHEDULE 13G EDGAR
  9. Aug 5, 2026S-8 POS EDGAR
  10. Aug 5, 2026S-8 POS EDGAR
  11. Aug 5, 2026S-8 POS EDGAR
  12. Aug 5, 2026S-8 POS EDGAR
  13. Aug 5, 2026S-8 POS EDGAR
  14. Aug 5, 2026S-8 POS EDGAR
  15. Aug 5, 2026S-8 POS EDGAR
  16. Aug 5, 2026S-8 POS EDGAR
  17. Aug 5, 2026S-8 POS EDGAR
  18. Aug 5, 2026S-8 POS EDGAR
  19. Aug 5, 2026S-8 POS EDGAR
  20. Aug 5, 2026S-8 EDGAR

The 352 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 0 buys and 69 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 10, 2026PATEL DINESH V PH DPresident and CEOSale7,278$144.10$1.0MForm 4
Sep 9, 2026PATEL DINESH V PH DPresident and CEOSale63,548$146.18$9.3MForm 4
Sep 8, 2026PATEL DINESH V PH DPresident and CEOSale54,174$145.87$7.9MForm 4
Aug 11, 2026PATEL DINESH V PH DPresident and CEOSale34,239$148.52$5.1MForm 4
Aug 10, 2026PATEL DINESH V PH DPresident and CEOSale65,761$149.11$9.8MForm 4
Jun 23, 2026Waddill William D.DirectorSale9,000$117.94$1.1MForm 4
Jun 10, 2026Waddill William D.DirectorSale9,000$107.68$969.1KForm 4
May 29, 2026Waddill William D.DirectorSale9,000$99.64$896.8KForm 4
May 12, 2026PATEL DINESH V PH DPresident and CEOSale75,000$100.12$7.5MForm 4
May 12, 2026PATEL DINESH V PH DPresident and CEOSale75,000$100.12$7.5MForm 4
May 8, 2026Giraudo BryanDirectorSale11,130$100.00$1.1MForm 4
May 7, 2026Giraudo BryanDirectorSale48,000$100.12$4.8MForm 4
Apr 20, 2026Ali AsifChief Financial OfficerSale1,750$105.47$184.6KForm 4
Mar 26, 2026MOLINA ARTURO MDChief Medical OfficerSale15,000$104.79$1.6MForm 4
Mar 26, 2026SELICK HAROLD EDirectorSale24,000$105.00$2.5MForm 4
Mar 26, 2026Ali AsifChief Financial OfficerSale24,765$104.24$2.6MForm 4
Mar 25, 2026PATEL DINESH V PH DPresident and CEOSale54,641$101.00$5.5MForm 4
Mar 24, 2026PATEL DINESH V PH DPresident and CEOSale59$101.00$6.0KForm 4
Feb 17, 2026Williams Lewis TDirectorSale18,000$82.42$1.5MForm 4
Feb 6, 2026Waddill William D.DirectorSale20,000$83.68$1.7MForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.10,307,837$1.3B0.0%+528,468
Farallon Capital Management, L.l.c.6,348,906$778.2M4.6%No change
Rtw Investments, LP5,061,175$620.4M5.3%+2,122
Vanguard Portfolio Management LLC3,629,298$444.9M0.0%+148,087
Wellington Management Group Llp3,416,781$418.8M0.1%−182,863
UBS Group AG3,399,221$416.7M0.1%−1,778,575
State Street Corp3,321,554$407.2M0.0%+204,805
Vanguard Capital Management LLC2,853,394$349.8M0.0%+47,498
Johnson & Johnson2,449,183$300.2M37.6%No change
Invesco Ltd.2,340,667$286.9M0.0%+175,997
Jupiter Topco LLC2,129,780$261.0M0.1%New
Geode Capital Management, LLC1,741,209$213.5M0.0%+71,838
Woodline Partners LP1,414,173$173.3M0.5%No change
Bank Of America Corp /de/1,324,498$162.4M0.0%+29,064
Jennison Associates LLC1,151,681$141.2M0.1%+79,670
Perceptive Advisors LLC981,879$120.4M1.9%−249,000
ADAR1 Capital Management, LLC960,863$117.8M5.6%−33,256
Morgan Stanley905,992$111.1M0.0%−112,230
Alyeska Investment Group, L.P.889,298$109.0M0.3%+296,101
Hood River Capital Management LLC882,738$108.2M0.8%+53,453
Goldman Sachs Group Inc812,852$99.6M0.0%+33,907
Driehaus Capital Management LLC731,053$89.6M0.5%+10,125
Clearbridge Investments, LLC725,335$88.9M0.1%+103,515
Fmr LLC672,186$82.4M0.0%+10,189
Northern Trust Corp666,105$81.7M0.0%+78,137

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47